Stocks and Investing
Stocks and Investing
Tue, November 22, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Mon, November 21, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Debjit Chattopadhyay Maintained (ALLO) at Strong Buy with Decreased Target to $29 on, Nov 21st, 2022
Published on 2024-10-28 00:17:07 - WOPRAI, Debjit Chattopadhyay
Debjit Chattopadhyay of HC Wainwright & Co., Maintained "Allogene Therapeutics, Inc." (ALLO) at Strong Buy with Decreased Target from $43 to $29 on, Nov 21st, 2022.
Debjit has made no other calls on ALLO in the last 4 months.
There are 4 other peers that have a rating on ALLO. Out of the 4 peers that are also analyzing ALLO, 1 agrees with Debjit's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Dane Leone of "Raymond James" Downgraded from Buy to Hold on, Wednesday, August 10th, 2022
These are the ratings of the 3 analyists that currently disagree with Debjit
- Kalpit Patel of "B. Riley Securities" Maintained at Strong Buy with Decreased Target to $18 on, Thursday, September 22nd, 2022
- Luca Issi of "RBC Capital" Maintained at Buy with Decreased Target to $32 on, Wednesday, August 10th, 2022
- Mark Breidenbach of "Oppenheimer" Maintained at Buy with Decreased Target to $35 on, Wednesday, August 10th, 2022
Contributing Sources